[Amended] Disclosure

What happened

Sam Chun Dang Pharm/Material Matters Related to Investment Decisions/(2026.10.01) Material Matters Related to Investment Decisions (Execution of Exclusive Canada Distribution and Supply Agreement for SCD411 (Vial & PFS), a Biosimilar of the Macular Degeneration Treatment Eylea (Active Ingredient: Aflibercept), and Additional Agreements for 6 Middle East Countries)

Amendment Report Amendment date: 2026-10-01 1. Disclosure document being amended: Execution of Exclusive Canada Distribution Right and Supply Agreement for SCD411 (Vial & PFS), a Biosimilar of the Macular Degeneration Treatment Eylea (Active Ingredient: Aflibercept) 2. Date of original disclosure document: 2026-10-01 3. Reason for amendment: Amendment due to an additional agreement 4. Amended Items

Item: 1. Title Before: Execution of Exclusive Canada Distribution and Supply Agreement for SCD411 (Vial & PFS), a Biosimilar of the Macular Degeneration Treatment Eylea (Active Ingredient: Aflibercept), and Additional Agreements for 6 Middle East Countries After: Execution of Exclusive Canada Distribution and Supply Agreement for SCD411 (Vial & PFS), a Biosimilar of the Macular Degeneration Treatment Eylea (Active Ingredient: Aflibercept), and Additional Agreements for 6 Middle East Countries; Addition of a New Product for Macular Degeneration Treatment

Item: 2. Key Content Before: (a) through (c) After: (a) through (c): Same as before. (d) A new product for macular degeneration treatment has been added for Canada and 6 Middle East countries; details cannot be disclosed at the partner's request.

[Special Matters Under the Contract, Investment Risk Factors] Before: (a) through (d) After: (a) through (d): Same as before. (e) With respect to the new product added under the October 1, 2026 supplementary agreement, if the agreement is terminated, the Company may be obligated to pay a termination fee within the scope of milestone payments already received, as set forth in the agreement.

[Matters Related to Disclosure Deferral] Before: 1 through 3 After: 1 through 2: Same as before. 3. Deferral deadline: 2036-10-01

- Material Matters Related to Investment Decisions

1. Title: Execution of Exclusive Canada Distribution and Supply Agreement for SCD411 (Vial & PFS), a Biosimilar of the Macular Degeneration Treatment Eylea (Active Ingredient: Aflibercept), and Additional Agreements for 6 Middle East Countries; Addition of a New Product for Macular Degeneration Treatment

2. Key Content (a) Counterparty: Apotex (Canada) (b) Content of Agreement (1) Agreement content: Exclusive distribution and sale rights in Canada for a biosimilar (Vial & PFS) of the macular degeneration treatment with aflibercept as the active ingredient (2) Upfront payment and milestone-related contract terms - Total amount: USD 15,000,000 (approx. KRW 20 billion) 1) Upfront payment (to be received within 30 days of contract execution): USD 3,000,000 (approx. KRW 4 billion) 2) Submission of regulatory filing to Health Canada: USD 2,000,000 (approx. KRW 2.7 billion) 3) Completion of Health Canada inspection: USD 2,000,000 (approx. KRW 2.7 billion) 4) Health Canada approval granted: USD 2,000,000 (approx. KRW 2.7 billion) 5) Registration of PFS formulation, 1st Group: USD 4,000,000 (approx. KRW 5.4 billion) 6) Cumulative Canada sales of CAD 10 million (approx. KRW 9.9 billion): USD 1,000,000 (approx. KRW 1.3 billion) 7) Cumulative Canada sales of CAD 20 million (approx. KRW 19.8 billion): USD 1,000,000 (approx. KRW 1.3 billion) * Milestones 2) through 7) are to be received within 60 days from the date each is achieved. (3) Matters related to product supply 1) Term: 10 years from the date of first product sale (automatically renewed every 2 years after the 10-year term) 2) Profit sharing: Net profit is settled quarterly by multiplying by the following ratios: - If this PFS product achieves its first insurance listing, or is listed within 3 months of another PFS product's first listing: 50% - If listed within 4-6 months after another PFS product's first insurance listing: 35% - Otherwise: 25% (c) This is an additional supply agreement for a new product covering Saudi Arabia and 5 other countries; the upfront payment, milestones, product name, and profit-sharing ratio cannot be disclosed at the counterparty's request. (d) A new product for macular degeneration treatment has been added for Canada and 6 Middle East countries; details cannot be disclosed at the partner's request.

3. Date of occurrence (confirmation) of the fact: 2023-08-23 4. Decision date: - - Outside director attendance: Present (-); Absent (-) - Audit committee member (non-outside-director) attendance: - 5. Other Important Matters Related to Investment Decisions (a) The date of occurrence (confirmation) above is the contract execution date. (b) The KRW-equivalent amounts above are calculated using the Seoul Money Brokerage Services exchange rate of KRW 1,338.20/USD as of 2023-08-23. (c) Revenue recognition under this agreement is conditional and may vary depending on the success of regulatory approval, etc.; there is also a possibility it will not be realized. (d) Regarding the development of SCD411, the Company has obtained approval and is currently selling the product in Canada.

※ Related Disclosures 2026-02-19 Material Matters Related to Investment Decisions (Execution of Exclusive Canada Distribution and Supply Agreement for SCD411 (Vial & PFS), a Biosimilar of the Macular Degeneration Treatment Eylea (Active Ingredient: Aflibercept), and Additional Agreements for 6 Middle East Countries)

[Special Matters Under the Contract, Investment Risk Factors] (a) There is no obligation to return any amount received at each stage, including the upfront payment described above, for any milestone received. (b) The above milestones are amounts received according to progress stage. (c) Revenue recognition under this agreement is conditional and may vary depending on the success of regulatory approval, etc.; there is also a possibility it will not be realized. (d) If regulatory approval is not obtained, this agreement may be terminated, and the Company will have no obligation to pay a penalty due to termination. (e) With respect to the new product added under the October 1, 2026 supplementary agreement, if the agreement is terminated, the Company may be obligated to pay a termination fee within the scope of milestone payments already received, as set forth in the agreement.

[Matters Related to Disclosure Deferral] 1. Deferred matters: Details such as contracted products, upfront payment and milestones, profit sharing, etc. 2. Reason for deferral: Counterparty's request to maintain business confidentiality 3. Deferral deadline: 2036-10-01